JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

Home・Akciju saraksts・Champions Oncology Inc

C
Champions Oncology Inc

Slēgts

SektorsVeselības aprūpe

7.03 -5.76

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

6.86

Max

7.46

Galvenie mērījumi
By Trading Economics
Ienākumi	702K 236K
Pārdošana	1M 15M
P/E Sektora vidējais	40.177 90.422
Peļņas marža	1.57
Darbinieki	213
EBITDA	1.1M 612K

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+57.48% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 10. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-13M 95M
Iepriekšējā atvēršanas cena	12.79
Iepriekšējā slēgšanas cena	7.03

Ziņu noskaņojums

By Acuity

50%

151 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

5.77 / 7.61 Atbalsts un pretestība

Champions Oncology Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. janv. 22:31 UTC

Peļņas

KLA Posts Higher 2Q Profit On Product and Services Sales Growth

2026. g. 29. janv. 22:05 UTC

Peļņas

Stryker Logs Higher 4Q Profit On Sales Gains

2026. g. 29. janv. 21:54 UTC

Peļņas

Visa 1Q Sales Climb on Strong Holiday Shopping -- Update

2026. g. 29. janv. 21:36 UTC

Peļņas

Visa 1Q Sales Climb on Strong Holiday Shopping

2026. g. 29. janv. 23:57 UTC

Iegādes, apvienošanās, pārņemšana

Aluminum Corp. of China: to Hold 67% of Joint Venture With Rio Tinto

2026. g. 29. janv. 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Aluminum Corp. of China: Deal Valued at Roughly BRL4.69 Billion

2026. g. 29. janv. 23:53 UTC

Iegādes, apvienošanās, pārņemšana

Aluminum Corp. of China Says It, Rio Tinto Propose to Buy 69% Stake in Companhia Brasileira de Aluminio S.A.

2026. g. 29. janv. 23:51 UTC

Peļņas

Correction to Intel Earnings Article on Jan. 22 -- WSJ

2026. g. 29. janv. 23:49 UTC

Tirgus saruna

Nikkei May Decline After Wall Street Tech Selloffs -- Market Talk

2026. g. 29. janv. 23:49 UTC

Tirgus saruna

Gold Rises Amid Ongoing Iran Tensions -- Market Talk

2026. g. 29. janv. 23:47 UTC

Tirgus saruna

Pro Medicus Looks Attractive Ahead of 1H Result -- Market Talk

2026. g. 29. janv. 23:35 UTC

Peļņas

Apple Posts Blowout iPhone Sales on Surging China Demand -- 2nd Update

2026. g. 29. janv. 23:32 UTC

Tirgus saruna

REA's 1H Result Could Jolt Share Price More Than Usual -- Market Talk

2026. g. 29. janv. 23:32 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 29. janv. 23:15 UTC

Tirgus saruna

Peļņas

Visa Says High Earners Still Lead Spending Growth -- Market Talk

2026. g. 29. janv. 22:27 UTC

Peļņas

Sandisk Beats Earnings. The Stock Is Soaring. -- Barrons.com

2026. g. 29. janv. 22:27 UTC

Peļņas

GE Vernova Gains After Earnings. Guidance Boost Was Enough to Lift the Stock. -- Barrons.com

2026. g. 29. janv. 22:12 UTC

Peļņas

Visa Beats Expectations on Stronger Spending. The Stock Is Falling. -- Barrons.com

2026. g. 29. janv. 21:55 UTC

Peļņas

Micron Stock Rises. Samsung Signals a 'Golden Era' for Memory Chips. -- Barrons.com

2026. g. 29. janv. 21:50 UTC

Tirgus saruna

Peļņas

Financial Services Roundup: Market Talk

2026. g. 29. janv. 21:50 UTC

Peļņas

These Stocks Are Today's Movers: Microsoft, Meta, Tesla, Joby Aviation, SAP, Royal Caribbean, and More -- Barrons.com

2026. g. 29. janv. 21:50 UTC

Tirgus saruna

Peļņas

Health Care Roundup: Market Talk

2026. g. 29. janv. 21:50 UTC

Tirgus saruna

Peļņas

Auto & Transport Roundup: Market Talk

2026. g. 29. janv. 21:49 UTC

Peļņas

Honeywell Delivers Solid Earnings Ahead of Its Corporate Breakup -- Barrons.com

2026. g. 29. janv. 21:46 UTC

Peļņas

Apple Posts Blowout iPhone Sales on Surging China Demand -- Update

2026. g. 29. janv. 21:36 UTC

Peļņas

Lockheed Martin Stock Jumps on Guidance and Government Missile Deal -- Barrons.com

2026. g. 29. janv. 21:32 UTC

Peļņas

Visa Beats Expectations on Stronger Spending. The Stock Is Falling. -- Barrons.com

2026. g. 29. janv. 21:32 UTC

Peļņas

Sandisk Beats Earnings. The Stock Is Soaring. -- Barrons.com

2026. g. 29. janv. 21:30 UTC

Peļņas

Apple Posts Blowout IPhone Sales on Surging China Demand -- WSJ

2026. g. 29. janv. 21:30 UTC

Peļņas

Apple 1Q Mac Rev $8.39B >AAPL

Salīdzinājums

Cenas izmaiņa

Champions Oncology Inc Prognoze

Cenas mērķis

By TipRanks

57.48% augšup

Prognoze 12 mēnešiem

Vidējais 12 USD 57.48%

Augstākais 12 USD

Zemākais 12 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Champions Oncology Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Champions Oncology Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

5.77 / 7.61Atbalsts un pretestība

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Noskaņojums

By Acuity

151 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.